PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)
CUSIP: 74587V107
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 49,633,071
- Total 13F shares
- 32,782,327
- Share change
- +2,453,997
- Total reported value
- $112,437,236
- Put/Call ratio
- 0%
- Price per share
- $3.43
- Number of holders
- 121
- Value change
- +$8,596,760
- Number of buys
- 64
- Number of sells
- 48
Quarterly Holders Quick Answers
What is CUSIP 74587V107?
CUSIP 74587V107 identifies PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74587V107:
Top shareholders of PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. |
13D/G
|
Anders Hove |
8%
|
3,940,052
|
$11,859,557 | +$1,988,442 | 31 Dec 2024 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
7.9%
|
3,940,052
|
$11,662,554 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.6%
from 13D/G
|
3,847,368
|
$11,388,209 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.4%
|
3,669,263
|
$10,861,018 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
4%
|
2,008,146
|
$5,940,000 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
3.9%
|
1,894,126
|
$5,701,319 | $0 | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
3.7%
|
1,829,213
|
$5,414,470 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
2.3%
|
1,149,660
|
$3,402,994 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
955,456
|
$2,828,529 | — | 31 Mar 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.8%
|
911,123
|
$2,696,924 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.8%
|
888,663
|
$2,631,648 | — | 31 Mar 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1.7%
|
831,689
|
$2,461,799 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.3%
|
649,792
|
$1,923,384 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.2%
|
571,665
|
$1,692,128 | — | 31 Mar 2025 | |
| GLOBEFLEX CAPITAL L P |
13F
|
Company |
0.91%
|
452,606
|
$1,339,714 | — | 31 Mar 2025 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.82%
|
406,854
|
$1,204,288 | — | 31 Mar 2025 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
0.72%
|
358,621
|
$1,061,518 | — | 31 Mar 2025 | |
| SEI INVESTMENTS CO |
13F
|
Company |
0.7%
|
347,679
|
$1,029,131 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.69%
|
340,886
|
$1,009,023 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.64%
|
317,438
|
$939,617 | — | 31 Mar 2025 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.62%
|
308,155
|
$912,139 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.59%
|
294,243
|
$870,960 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.56%
|
279,667
|
$827,814 | — | 31 Mar 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.56%
|
275,788
|
$816,332 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.53%
|
262,538
|
$777,113 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.5%
|
246,800
|
$730,528 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.44%
|
216,413
|
$640,582 | — | 31 Mar 2025 | |
| Alvin F. Wong |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
201,187
mixed-class rows
|
$633,593 | — | 12 Feb 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.4%
|
200,962
|
$594,848 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.4%
|
200,000
|
$592,000 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.39%
|
192,800
|
$570,688 | — | 31 Mar 2025 | |
| Prospera Financial Services Inc |
13F
|
Company |
0.37%
|
184,257
|
$545,391 | — | 31 Mar 2025 | |
| Jeffrey Jerome Ludwig |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
223,013
mixed-class rows
|
$494,161 | — | 07 Feb 2025 | |
| MACKENZIE FINANCIAL CORP |
13F
|
Company |
0.32%
|
157,713
|
$466,830 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.31%
|
152,943
|
$452,711 | — | 31 Mar 2025 | |
| STRS OHIO |
13F
|
Company |
0.29%
|
141,900
|
$420,024 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.26%
|
127,174
|
$376,435 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.25%
|
125,317
|
$370,938 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.24%
|
118,254
|
$350,032 | — | 31 Mar 2025 | |
| Brian M. Stuglik |
3/4/5
|
Director |
0.19%
|
94,958
|
$321,907 | -$27,459 | 13 Jun 2025 | |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC |
13F
|
Company |
0.22%
|
107,945
|
$319,517 | — | 31 Mar 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.2%
|
99,394
|
$294,000 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.19%
|
93,087
|
$275,537 | — | 31 Mar 2025 | |
| Allison Dorval |
3/4/5
|
Director |
0.15%
|
75,390
|
$256,326 | -$39,474 | 13 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.17%
|
85,999
|
$254,000 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.17%
|
83,261
|
$246,453 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.16%
|
81,100
|
$240,056 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.16%
|
79,101
|
$234,139 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.16%
|
78,175
|
$231,398 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.16%
|
77,328
|
$228,891 | — | 31 Mar 2025 |
Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2025
As of 30 Jun 2025,
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) was held by
121 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,782,327 shares.
The largest 10 holders included
ACORN CAPITAL ADVISORS, LLC, BlackRock, Inc., VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, AMERICAN CENTURY COMPANIES INC, DIMENSIONAL FUND ADVISORS LP, KENNEDY CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, and Connor, Clark & Lunn Investment Management Ltd..
This page lists
120
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
116
Q2 2025 holders
121
Holder diff
5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.